Skip to main content
main-content
Oncology

KEYNOTE-057 supports pembrolizumab for BCG-unresponsive bladder cancer

Vial_syringe 2

The PD-1 inhibitor pembrolizumab shows promising antitumor activity in people with BCG-unresponsive non-muscle-invasive bladder cancer with or without papillary tumors, show data from the phase 2 KEYNOTE-057 trial.

Rheumatology

Methotrexate may impair immune response to COVID-19 vaccination

Doctor giving a senior woman a vaccination

Some patients with immune-mediated inflammatory diseases treated with methotrexate may have a blunted immune response to mRNA vaccines against SARS-CoV-2, researchers report.

Headlines from across medwireNews

11-06-2021 | Oncology | News | Article

Patient survey points to need for innovative dosing strategies in MBC

The high side-effect burden of metastatic breast cancer treatments warrants the development of innovative dosing strategies to maintain quality of life, suggest the results of an advocate-led survey of patients.

11-06-2021 | Rheumatology | News | Article

COVID-19 antibody data reassuring for people with SLE

The majority of patients with systemic lupus erythematosus and confirmed COVID-19 are able to produce a durable antibody response to the infection, despite the use of immunosuppressants, US research suggests.

11-06-2021 | Oncology | News | Article

Cytotoxic therapy linked to excess long-term mortality in testicular cancer survivors

Men who receive platinum-based chemotherapy or radiotherapy for testicular cancer have significantly higher long-term non-testicular cancer mortality rates than the general population, study findings indicate.

10-06-2021 | Diabetes | News | Article

Steep eGFR drop on SGLT2 inhibitor initiation may pose cardiorenal risk

The small proportion of people who experience an eGFR fall of more than 30% on starting an SGLT2 inhibitor may be at increased risk for adverse outcomes, research suggests.

10-06-2021 | Oncology | News | Article

Long-term benefits to neoadjuvant durvalumab in triple-negative breast cancer

Adding the PD-L1 inhibitor durvalumab to neoadjuvant chemotherapy may improve survival outcomes in people with triple-negative breast cancer, show GeparNUEVO data presented at the 2021 ASCO Annual Meeting.

10-06-2021 | Rheumatology | News | Article

Inflammation not accurately reflected by tender joints in RA

Tender joints in patients with rheumatoid arthritis may not be a suitable indicator of inflammation, study findings show.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make medwireNews.com your preferred medical news resource.

Meet the team

Image Credits